Last week saw a number of broker notes hitting the wires once again. Three buy ratings that investors might want to be aware of are summarised below.
Here's why brokers think investors ought to buy them next week:
Bapcor Ltd (ASX: BAP)
According to a note out of Citi, its analysts have retained their buy rating on this auto parts retailer's shares with an improved price target of $9.18. This follows the release of the company's half year results. Citi was happy with the results but is particularly positive on Bapcor's transformation program and believes it will offset any short term performance risks. It also feels that any inventory concerns are unnecessary and expects levels to moderate in the second half. The Bapcor share price ended the week at $6.33.
CSL Limited (ASX: CSL)
A note out of Morgans reveals that its analysts have retained their add rating and lifted their price target on this biotherapeutics company's shares to $337.92. Morgans was pleased with CSL's results and believes that its strong plasma collections and ongoing demand across both Behring and Seqirus, coupled with Vifor's added breadth, suggests strong growth and momentum ahead. The CSL share price was fetching $298.40 at Friday's close.
Endeavour Group Ltd (ASX: EDV)
Another note out of Morgans reveals that its analysts have upgraded this drinks giant's shares to an add rating with an improved price target of $7.80. This follows the release of Endeavour's half year result, which was comfortably ahead of expectations. And while Morgans acknowledges that the regulatory environment remains uncertain, it feels that the risks are to the upside with the underlying business performing well. The Endeavour share price ended the week at $6.78.
